Do GCKR rs1260326 and G6PC2 rs560887 variants shift the fasting glucose setpoint?

The human "glucostat" system, which establishes basal blood glucose levels, is heavily influenced by specific genetic variations that coordinate liver and pancreas physiology.

Hepatic glucose regulation via GCKR

• The GCKR rs1260326 (P446L) variant directly alters hepatic glucose handling to shift the fasting glucose setpoint downward.
• Mechanistically, the T (L446) allele weakens fructose-6-phosphate (F6P)-dependent nuclear sequestration of glucokinase (GCK) by its regulatory protein (GKRP). This leads to persistently higher cytosolic GCK activity and enhanced hepatic glucose clearance.
• While this mechanism reduces fasting glucose and type 2 diabetes risk, it simultaneously shunts carbon into de novo lipogenesis, which elevates circulating triglyceride levels.

Pancreatic islet glucose sensing via G6PC2

• The G6PC2 rs560887 variant modulates the pancreatic islet glucose-sensing threshold.
• In beta-cells, G6PC2 hydrolyzes glucose-6-phosphate back to glucose, opposing glucokinase and establishing a futile substrate cycle that regulates insulin secretion.
• The rs560887 A allele reduces G6PC2 pre-mRNA splicing efficiency, decreasing G6PC2 expression. This dampens the futile cycle, permitting greater glycolytic flux and triggering insulin release at a lower glycemic threshold.
• Additionally, G6PC2 acts in alpha-cells to define the setpoint for glucose-mediated glucagon suppression, lowering fasting plasma glucose and HbA1c without altering type 2 diabetes risk.

Bottom line

• GCKR rs1260326 and G6PC2 rs560887 act as core genetic modulators of the fasting glucose setpoint. GCKR shifts this setpoint by altering hepatic glucose clearance and lipogenesis, while G6PC2 shifts it by lowering the pancreatic islet threshold for insulin and glucagon release.